Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process

Min Soo Kim, Shun Ji Jin, Jeong Soo Kim, Hee Jun Park, Ha Seung Song, Reinhard H.H. Neubert, Sung Joo Hwang

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

In this work, amorphous atorvastatin calcium nanoparticles were successfully prepared using the supercritical antisolvent (SAS) process. The effect of process variables on particle size and distribution of atorvastatin calcium during particle formation was investigated. Solid state characterization, solubility, intrinsic dissolution, powder dissolution studies and pharmacokinetic study in rats were performed. Spherical particles with mean particle size ranging between 152 and 863 nm were obtained by varying process parameters such as precipitation vessel pressure and temperature, drug solution concentration and feed rate ratio of CO2/drug solution. XRD, TGA, FT-IR, FT-Raman, NMR and HPLC analysis indicated that atorvastatin calcium existed as anhydrous amorphous form and no degradation occurred after SAS process. When compared with crystalline form (unprocessed drug), amorphous atorvastatin calcium nanoparticles were of better performance in solubility and intrinsic dissolution rate, resulting in higher solubility and faster dissolution rate. In addition, intrinsic dissolution rate showed a good correlation with the solubility. The dissolution rates of amorphous atorvastatin calcium nanoparticles were highly increased in comparison with unprocessed drug by the enhancement of intrinsic dissolution rate and the reduction of particle size resulting in an increased specific surface area. The absorption of atorvastatin calcium after oral administration of amorphous atorvastatin calcium nanoparticles to rats was markedly increased.

Original languageEnglish
Pages (from-to)454-465
Number of pages12
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume69
Issue number2
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Nanoparticles
Solubility
Particle Size
Pharmaceutical Preparations
Atorvastatin Calcium
Powders
Oral Administration
Pharmacokinetics
High Pressure Liquid Chromatography
Pressure
Temperature

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Pharmaceutical Science

Cite this

Kim, Min Soo ; Jin, Shun Ji ; Kim, Jeong Soo ; Park, Hee Jun ; Song, Ha Seung ; Neubert, Reinhard H.H. ; Hwang, Sung Joo. / Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. In: European Journal of Pharmaceutics and Biopharmaceutics. 2008 ; Vol. 69, No. 2. pp. 454-465.
@article{da95c8c42d22440890cbb520dbb01085,
title = "Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process",
abstract = "In this work, amorphous atorvastatin calcium nanoparticles were successfully prepared using the supercritical antisolvent (SAS) process. The effect of process variables on particle size and distribution of atorvastatin calcium during particle formation was investigated. Solid state characterization, solubility, intrinsic dissolution, powder dissolution studies and pharmacokinetic study in rats were performed. Spherical particles with mean particle size ranging between 152 and 863 nm were obtained by varying process parameters such as precipitation vessel pressure and temperature, drug solution concentration and feed rate ratio of CO2/drug solution. XRD, TGA, FT-IR, FT-Raman, NMR and HPLC analysis indicated that atorvastatin calcium existed as anhydrous amorphous form and no degradation occurred after SAS process. When compared with crystalline form (unprocessed drug), amorphous atorvastatin calcium nanoparticles were of better performance in solubility and intrinsic dissolution rate, resulting in higher solubility and faster dissolution rate. In addition, intrinsic dissolution rate showed a good correlation with the solubility. The dissolution rates of amorphous atorvastatin calcium nanoparticles were highly increased in comparison with unprocessed drug by the enhancement of intrinsic dissolution rate and the reduction of particle size resulting in an increased specific surface area. The absorption of atorvastatin calcium after oral administration of amorphous atorvastatin calcium nanoparticles to rats was markedly increased.",
author = "Kim, {Min Soo} and Jin, {Shun Ji} and Kim, {Jeong Soo} and Park, {Hee Jun} and Song, {Ha Seung} and Neubert, {Reinhard H.H.} and Hwang, {Sung Joo}",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.ejpb.2008.01.007",
language = "English",
volume = "69",
pages = "454--465",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "2",

}

Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. / Kim, Min Soo; Jin, Shun Ji; Kim, Jeong Soo; Park, Hee Jun; Song, Ha Seung; Neubert, Reinhard H.H.; Hwang, Sung Joo.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, No. 2, 01.06.2008, p. 454-465.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process

AU - Kim, Min Soo

AU - Jin, Shun Ji

AU - Kim, Jeong Soo

AU - Park, Hee Jun

AU - Song, Ha Seung

AU - Neubert, Reinhard H.H.

AU - Hwang, Sung Joo

PY - 2008/6/1

Y1 - 2008/6/1

N2 - In this work, amorphous atorvastatin calcium nanoparticles were successfully prepared using the supercritical antisolvent (SAS) process. The effect of process variables on particle size and distribution of atorvastatin calcium during particle formation was investigated. Solid state characterization, solubility, intrinsic dissolution, powder dissolution studies and pharmacokinetic study in rats were performed. Spherical particles with mean particle size ranging between 152 and 863 nm were obtained by varying process parameters such as precipitation vessel pressure and temperature, drug solution concentration and feed rate ratio of CO2/drug solution. XRD, TGA, FT-IR, FT-Raman, NMR and HPLC analysis indicated that atorvastatin calcium existed as anhydrous amorphous form and no degradation occurred after SAS process. When compared with crystalline form (unprocessed drug), amorphous atorvastatin calcium nanoparticles were of better performance in solubility and intrinsic dissolution rate, resulting in higher solubility and faster dissolution rate. In addition, intrinsic dissolution rate showed a good correlation with the solubility. The dissolution rates of amorphous atorvastatin calcium nanoparticles were highly increased in comparison with unprocessed drug by the enhancement of intrinsic dissolution rate and the reduction of particle size resulting in an increased specific surface area. The absorption of atorvastatin calcium after oral administration of amorphous atorvastatin calcium nanoparticles to rats was markedly increased.

AB - In this work, amorphous atorvastatin calcium nanoparticles were successfully prepared using the supercritical antisolvent (SAS) process. The effect of process variables on particle size and distribution of atorvastatin calcium during particle formation was investigated. Solid state characterization, solubility, intrinsic dissolution, powder dissolution studies and pharmacokinetic study in rats were performed. Spherical particles with mean particle size ranging between 152 and 863 nm were obtained by varying process parameters such as precipitation vessel pressure and temperature, drug solution concentration and feed rate ratio of CO2/drug solution. XRD, TGA, FT-IR, FT-Raman, NMR and HPLC analysis indicated that atorvastatin calcium existed as anhydrous amorphous form and no degradation occurred after SAS process. When compared with crystalline form (unprocessed drug), amorphous atorvastatin calcium nanoparticles were of better performance in solubility and intrinsic dissolution rate, resulting in higher solubility and faster dissolution rate. In addition, intrinsic dissolution rate showed a good correlation with the solubility. The dissolution rates of amorphous atorvastatin calcium nanoparticles were highly increased in comparison with unprocessed drug by the enhancement of intrinsic dissolution rate and the reduction of particle size resulting in an increased specific surface area. The absorption of atorvastatin calcium after oral administration of amorphous atorvastatin calcium nanoparticles to rats was markedly increased.

UR - http://www.scopus.com/inward/record.url?scp=43249110027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249110027&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2008.01.007

DO - 10.1016/j.ejpb.2008.01.007

M3 - Article

C2 - 18359211

AN - SCOPUS:43249110027

VL - 69

SP - 454

EP - 465

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 2

ER -